Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Acusphere Inc

+ Add to Watchlist

ACUS:US

0.0700 USD 0.0090 11.39%

As of 20:10:01 ET on 05/19/2015.

Snapshot for Acusphere Inc (ACUS)

Open: 0.0790 Day's Range: 0.0700 - 0.0790 Volume: 26,367
Previous Close: 0.0790 52wk Range: 0.0550 - 1.0000 1-Yr Rtn: -91.25%

Stock Chart for ACUS

No chart data available.
  • ACUS:US 0.0700
  • 1D
  • 1M
  • 1Y
0.0790
Interactive ACUS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ACUS

Current P/E Ratio (ttm) -
Estimated P/E(12/2009) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -12.6000
Est. EPS (USD) (12/2009) -
Est. PEG Ratio -
Market Cap (M USD) 0.35
Shares Outstanding (M) 4.95
30 Day Average Volume 4,485
Price/Book (mrq) -
Price/Sale (ttm) 0.1238
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ACUS

No data available

Company Profile & Key Executives for ACUS

Acusphere, Inc., a specialty pharmaceutical company, develops new drugs and improved formulations for existing drugs. The Company utilizes porous microparticle technology. The company's three initial product candidates are in clinical development. The lead product candidate is a cardiovascular drug in Phase III clinical development for the detection of coronary artery disease.

Martyn D GreenacreChairmanSherri Carroll ObergVice Chairman/Co-Founder
William I RamageChief Development Officer
More Company Profile & Key Executives for ACUS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil